{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,7]],"date-time":"2026-01-07T07:50:22Z","timestamp":1767772222923,"version":"3.37.1"},"reference-count":19,"publisher":"Japanese Society of Internal Medicine","issue":"4","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Intern. Med."],"published-print":{"date-parts":[[2025,2,15]]},"DOI":"10.2169\/internalmedicine.3467-24","type":"journal-article","created":{"date-parts":[[2024,7,10]],"date-time":"2024-07-10T22:12:39Z","timestamp":1720649559000},"page":"609-612","source":"Crossref","is-referenced-by-count":1,"title":["Melanoma Differentiation-associated Gene 5-Positive Rapidly Progressive Interstitial Lung Disease Successfully Treated with Tofacitinib"],"prefix":"10.2169","volume":"64","author":[{"given":"Kunika","family":"Shimizu","sequence":"first","affiliation":[{"name":"Division of Rheumatology, Department of Medicine, Showa University School of Medicine, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ryo","family":"Yanai","sequence":"additional","affiliation":[{"name":"Division of Rheumatology, Department of Medicine, Showa University School of Medicine, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kie","family":"Yamamoto","sequence":"additional","affiliation":[{"name":"Division of Rheumatology, Department of Medicine, Showa University School of Medicine, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yuta","family":"Michizu","sequence":"additional","affiliation":[{"name":"Division of Rheumatology, Department of Medicine, Showa University School of Medicine, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yuzo","family":"Ikari","sequence":"additional","affiliation":[{"name":"Division of Rheumatology, Department of Medicine, Showa University School of Medicine, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nobuyuki","family":"Yajima","sequence":"additional","affiliation":[{"name":"Division of Rheumatology, Department of Medicine, Showa University School of Medicine, Japan"},{"name":"Department of Healthcare Epidemiology, School of Public Health in the Graduate School of Medicine, Kyoto University, Japan"},{"name":"Center for Innovative Research for Communities and Clinical Excellence, Fukushima Medical University, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"962","reference":[{"key":"1","doi-asserted-by":"crossref","unstructured":"1. Hensgens MPM, Delemarre EM, Drylewicz J, et al. Clinical features and immune-related protein patterns of anti-MDA5 positive clinically amyopathic dermatomyositis Dutch patients. Rheumatology (Oxford) 61: 4087-4096, 2022.","DOI":"10.1093\/rheumatology\/keac030"},{"key":"2","doi-asserted-by":"crossref","unstructured":"2. Tsuji H, Nakashima R, Hosono Y, et al. Multicenter prospective study of the efficacy and safety of combined immunosuppressive therapy with high-dose glucocorticoid, tacrolimus, and cyclophosphamide in interstitial lung diseases accompanied by anti-melanoma differentiation-associated gene 5-positive dermatomyositis. Arthritis Rheumatol 72: 488-498, 2020.","DOI":"10.1002\/art.41105"},{"key":"3","doi-asserted-by":"crossref","unstructured":"3. Nakashima R, Imura Y, Kobayashi S, et al. The RIG-I-like receptor IFIH1\/MDA5 is a dermatomyositis-specific autoantigen identified by the anti-CADM-140 antibody. Rheumatology (Oxford) 49: 433-440, 2010.","DOI":"10.1093\/rheumatology\/kep375"},{"key":"4","doi-asserted-by":"crossref","unstructured":"4. Sato S, Murakami A, Kuwajima A, et al. Clinical utility of an enzyme-linked immunosorbent assay for detecting anti-melanoma differentiation-associated gene 5 autoantibodies. PLoS One 11: e0154285, 2016.","DOI":"10.1371\/journal.pone.0154285"},{"key":"5","doi-asserted-by":"publisher","unstructured":"5. Nakashima R, Hosono Y, Mimori T. Clinical significance and new detection system of autoantibodies in myositis with interstitial lung disease. Lupus 25: 925-933, 2016.","DOI":"10.1177\/0961203316651748"},{"key":"6","doi-asserted-by":"crossref","unstructured":"6. Romero-Bueno F, Diaz Del Campo P, Trallero-Aragu\u00e1s E, et al. Recommendations for the treatment of anti-melanoma differentiation-associated gene 5-positive dermatomyositis-associated rapidly progressive interstitial lung disease. Semin Arthritis Rheum 50: 776-790, 2020.","DOI":"10.1016\/j.semarthrit.2020.03.007"},{"key":"7","doi-asserted-by":"crossref","unstructured":"7. Shirakashi M, Nakashima R, Tsuji H, et al. Efficacy of plasma exchange in anti-MDA5-positive dermatomyositis with interstitial lung disease under combined immunosuppressive treatment. Rheumatology (Oxford) 59: 3284-3292, 2020.","DOI":"10.1093\/rheumatology\/keaa123"},{"key":"8","doi-asserted-by":"crossref","unstructured":"8. Hong LE, Proudman S, Limaye V. Interstitial pneumonia with autoimmune features in a patient with melanoma differentiation-associated gene 5 (MDA5) antibody. BMJ Case Rep 13: e234946, 2020.","DOI":"10.1136\/bcr-2020-234946"},{"key":"9","doi-asserted-by":"crossref","unstructured":"9. Chen Z, Wang X, Ye S. Tofacitinib in amyopathic dermatomyositis-associated interstitial lung disease. N Engl J Med 381: 291-293, 2019.","DOI":"10.1056\/NEJMc1900045"},{"key":"10","doi-asserted-by":"crossref","unstructured":"10. Kurasawa K, Arai S, Namiki Y, et al. Tofacitinib for refractory interstitial lung diseases in anti-melanoma differentiation-associated 5 gene antibody-positive dermatomyositis. Rheumatology (Oxford) 57: 2114-2119, 2018.","DOI":"10.1093\/rheumatology\/key188"},{"key":"11","doi-asserted-by":"crossref","unstructured":"11. Zhang SH, Zhao Y, Xie QB, Jiang Y, Wu YK, Yan B. Aberrant activation of the type I interferon system may contribute to the pathogenesis of anti-melanoma differentiation-associated gene 5 dermatomyositis. Br J Dermatol 180: 1090-1098, 2019.","DOI":"10.1111\/bjd.16917"},{"key":"12","doi-asserted-by":"crossref","unstructured":"12. Ytterberg SR, Bhatt DL, Mikuls TR, et al. Cardiovascular and cancer risk with tofacitinib in rheumatoid arthritis. N Engl J Med 386: 316-326, 2022.","DOI":"10.1056\/NEJMoa2109927"},{"key":"13","doi-asserted-by":"crossref","unstructured":"13. Winthrop KL, Yamanaka H, Valdez H, et al. Herpes zoster and tofacitinib therapy in patients with rheumatoid arthritis. Arthritis Rheumatol 66: 2675-2684, 2014.","DOI":"10.1002\/art.38745"},{"key":"14","doi-asserted-by":"crossref","unstructured":"14. Mease P, Charles-Schoeman C, Cohen S, et al. Incidence of venous and arterial thromboembolic events reported in the tofacitinib rheumatoid arthritis, psoriasis and psoriatic arthritis development programmes and from real-world data. Ann Rheum Dis 79: 1400-1413, 2020.","DOI":"10.1136\/annrheumdis-2019-216761"},{"key":"15","doi-asserted-by":"crossref","unstructured":"15. Jamilloux Y, El Jammal T, Vuitton L, Gerfaud-Valentin M, Kerever S, S\u00e8ve P. JAK inhibitors for the treatment of autoimmune and inflammatory diseases. Autoimmun Rev 18: 102390, 2019.","DOI":"10.1016\/j.autrev.2019.102390"},{"key":"16","doi-asserted-by":"crossref","unstructured":"16. Kotyla PJ, Engelmann M, Giemza-Stok\u0142osa J, Wnuk B, Islam MA. Thromboembolic adverse drug reactions in Janus kinase (JAK) inhibitors: does the inhibitor specificity play a role? Int J Mol Sci 22: 2449, 2021.","DOI":"10.3390\/ijms22052449"},{"key":"17","doi-asserted-by":"crossref","unstructured":"17. Barbar S, Noventa F, Rossetto V, et al. A risk assessment model for the identification of hospitalized medical patients at risk for venous thromboembolism: the Padua Prediction Score. J Thromb Haemost 8: 2450-2457, 2010.","DOI":"10.1111\/j.1538-7836.2010.04044.x"},{"key":"18","doi-asserted-by":"crossref","unstructured":"18. Ugajin M, Kani H, Hattori H. Anticoagulant use as an independent risk factor and higher in-hospital mortality in patients showing alveolar hemorrhage in diffuse lung disease. Medicina (Kaunas) 57: 1094, 2021.","DOI":"10.3390\/medicina57101094"},{"key":"19","doi-asserted-by":"crossref","unstructured":"19. Kreuter M, Wijsenbeek MS, Vasakova M, et al. Unfavourable effects of medically indicated oral anticoagulants on survival in idiopathic pulmonary fibrosis. Eur Respir J 47: 1776-1784, 2016.","DOI":"10.1183\/13993003.02087-2015"}],"container-title":["Internal Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/internalmedicine\/64\/4\/64_3467-24\/_pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,2,15]],"date-time":"2025-02-15T03:31:17Z","timestamp":1739590277000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/internalmedicine\/64\/4\/64_3467-24\/_article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,2,15]]},"references-count":19,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2025]]}},"URL":"https:\/\/doi.org\/10.2169\/internalmedicine.3467-24","relation":{},"ISSN":["0918-2918","1349-7235"],"issn-type":[{"type":"print","value":"0918-2918"},{"type":"electronic","value":"1349-7235"}],"subject":[],"published":{"date-parts":[[2025,2,15]]},"article-number":"3467-24"}}